Targeted therapy combination extends survival in BRAF -mutant melanoma
CHICAGO — Adjuvant dabrafenib plus trametinib reduced mortality risk for adults with resected stage III BRAF V600-mutant melanoma, according to final results of the randomized phase 3 COMBI-AD trial. The findings, presented at ASCO Annual Meeting, also reaffirmed 3- and 5-year updates on improved RFS and distant metastasis-free survival for individuals in the study’s treatment arm.
Source: healio.com
